The United Arab Emirates says a Chinese coronavirus vaccine Sinopharm tested in the federation of sheikhdoms is 86 per cent effective.
The UAE conducted a trial beginning in September of the vaccine by Chinese state-owned pharmaceutical giant Sinopharm involving 31,000 volunteers from 125 nations. Volunteers between 18 and 60 years old received two doses of the vaccine over 28 days.
The Health and Prevention Ministry of UAE announced that "have reviewed Sinopharm CNBG’s interim analysis of the Phase III trials".
The Ministry also said in a statement carried by the state news agency that "The analysis also shows "99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease" Also "The analysis shows no serious safety concerns" he added.
The UAE population of around 9 million, has recorded 178,837 infections and 596 deaths from the disease. Coronavirus vaccine Sinopharm is among the three most advanced candidates from China in terms of development and has been used to vaccinate around one million people in the country under its emergency use programme.
However, In July, the Gulf Arab state started Phase III clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG) and In September, it authorised emergency use of the vaccine for certain groups, the first such international clearance for a vaccine developed in China.